ZG-0418 is under clinical development by Suzhou Zelgen Biopharmaceutical and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ZG-0418’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ZG-0418 is under development for the treatment of advanced ALK-positive or ROS1-positive non-small cell lung cancer. It is administered through oral route in the form of capsule and tablet. The drug candidate acts by targeting the ALK Kinase and receptor tyrosine kinase c Ros oncogene 1 (ROS1).
Suzhou Zelgen Biopharmaceutical overview
Suzhou Zelgen Biopharmaceutical (Zelgen) is a pharmaceutical company that carries out research and development and production of innovative medicines. The company develops a product pipeline of small molecule new drugs and recombinant protein new drugs which covers liver cancer, non-small cell lung cancer, colorectal cancer, thyroid cancer, nasopharyngeal cancer, myeloproliferative neoplasms cancers, hematological tumors, hemorrhage, immune-inflammatory diseases, liver and gallbladder diseases and other therapeutic areas. Zelgen operates its drug research and development center in CHina and the US. Zelgen is headquartered in Kunshan, Jiangsu, China.
For a complete picture of ZG-0418’s drug-specific PTSR and LoA scores, buy the report here.